Inverse Relationship between Serum VEGF Levels and Late In-Stent Restenosis of Drug-Eluting Stents

被引:3
|
作者
Yin, Jiasheng [1 ]
Shen, Li [1 ,2 ]
Ji, Meng [1 ]
Wu, Yizhe [1 ,2 ]
Cai, Sishi [1 ]
Chen, Jiahui [1 ,2 ]
Yao, Zhifeng [1 ,2 ]
Ge, Junbo [1 ,2 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Shanghai Inst Cardiovasc Dis, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Cardiol, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
ANGIOGRAPHIC PATTERNS; BARE-METAL; NEOATHEROSCLEROSIS; IMPLANTATION; INJURY; RISK;
D O I
10.1155/2017/8730271
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Late in-stent restenosis (ISR) has raised concerns regarding the long-term efficacy of drug-eluting stents (DES). The role of vascular endothelial growth factor (VEGF) in the pathological process of ISR is controversial. This retrospective study aimed to investigate the relationship between serum VEGF levels and late ISR in patients with DES implantation. A total of 158 patients who underwent angiography follow-up beyond 1 year after intervention were included. The study population was classified into ISR and non-ISR groups. The ISR group was further divided according to follow-up duration and Mehran classification. VEGF levels were significantly lower in the ISR group than in the non-ISR group [96.34 (48.18, 174.14) versus 179.14 (93.59, 307.74) pg/mL, P < 0.0001]. Multivariate regression revealed that VEGF level, procedure age, and low-density lipoprotein cholesterol were independent risk factors for late ISR formation. Subgroup analysis demonstrated that VEGF levels were even lower in the very late (>= 5 years) and diffuse ISR group (Mehran patterns II, III, and IV) than in the late ISR group (1-4 years) and the focal ISR group (Mehran pattern I), respectively. Furthermore, significant difference was found between diffuse and focal ISR groups. Serum VEGF levels were inversely associated with late ISR after DES implantation.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] A Renewed Application of Intracoronary Brachytherapy for In-Stent Restenosis of Drug-Eluting Stents
    Ohri, N.
    Sharma, S.
    Kini, A.
    Baber, U.
    Aquino, M.
    Roy, S.
    Sayeneni, S.
    Wright, F.
    Buckstein, M.
    Bakst, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S685 - S685
  • [22] Drug-eluting stent versus drug-eluting balloon for in-stent restenosis treatment
    Villanueva Benito, I.
    Solla Ruiz, I.
    Paredes Galan, E.
    Bastos Fernandez, G.
    De Miguel, A.
    Gomez Blazquez, I.
    Ortiz Saez, A.
    Jimenez Diaz, V.
    Baz Alonso, J. A.
    Iniguez Romo, A.
    EUROPEAN HEART JOURNAL, 2011, 32 : 490 - 490
  • [23] Drug-Eluting Balloon Therapy for In-Stent Restenosis of Drug-Eluting Stents Choose and Prepare the Appropriate Lesion
    Brott, Brigitta C.
    Chatterjee, Arka
    JACC-CARDIOVASCULAR INTERVENTIONS, 2018, 11 (10) : 979 - 980
  • [24] Everolimus Eluting Stents Versus First Generation Drug Eluting Stents (Sirolimus or Paclitaxel) for Treatment of Drug-Eluting Stent In-Stent Restenosis
    Goel, Sachin
    El-Mallah, Wael
    Ige, Mobolaji
    Gupta, Supriya
    Tuzcu, E. Murat
    Ellis, Stephen
    Kapadia, Samir
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (17) : B194 - B194
  • [25] Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
    Wang, Guozhong
    Zhao, Quanming
    Chen, Qing
    Zhang, Xiaoxia
    Tian, Lei
    Zhang, Xiaojiang
    CORONARY ARTERY DISEASE, 2019, 30 (07) : 473 - 480
  • [26] Kissing drug eluting balloons for in-stent restenosis complicating bifurcations treated with drug-eluting stents
    Raja, Yogesh
    Doshi, Sagar N.
    Townend, Jonathan N.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2012, 79 (03) : 392 - 396
  • [27] Incidence and predictors of recurrent restenosis following implantation of drug-eluting stents for in-stent restenosis
    Lee, Cheol Whan
    Park, Chang-Bum
    Kim, Young-Hak
    Hong, Myeong-Ki
    Kim, Jae-Joong
    Park, Seong-Wook
    Park, Seung-Jung
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2007, 69 (01) : 104 - 108
  • [28] Outcome Differences With the Use of Drug-Eluting Stents for the Treatment of In-Stent Restenosis of Bare-Metal Stents Versus Drug-Eluting Stents
    Steinberg, Daniel H.
    Gaglia, Michael A., Jr.
    Slottow, Tina L. Pinto
    Roy, Probal
    Bonello, Laurent
    De Labriolle, Axel
    Lemesle, Gilles
    Torguson, Rebecca
    Kineshige, Kimberly
    Xue, Zhenyi
    Suddath, William O.
    Kent, Kenneth M.
    Satler, Lowell F.
    Pichard, Augusto D.
    Lindsay, Joseph
    Waksman, Ron
    AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (04): : 491 - 495
  • [29] Evaluation and management of drug-eluting stent in-stent restenosis
    Parfrey, Shane
    Siu, Vincent J.
    Graham, John
    Vijayaraghavan, Ram
    Li, Christopher
    Pang, Jeffrey
    Kalra, Sanjog
    Dzavik, Vladimir C.
    Wijeysundera, Harindra
    Bagai, Akshay
    CURRENT OPINION IN CARDIOLOGY, 2023, 38 (05) : 433 - 440
  • [30] The association between serum eosinophil cationic protein levels and late restenosis in patients with drug-eluting stents
    Wu, Y. Z.
    Yin, J.
    Cai, S. S.
    Shen, L.
    Ji, M.
    Yao, Z. F.
    Ge, J. B.
    EUROPEAN HEART JOURNAL, 2017, 38 : 1279 - 1279